Lineage, Inc. (LINE) Peer Comparison
$40.56
$-0.68
(-1.65%)
As on 26-Aug-2026 16:00EDT
Market cap
$10,434 Mln
Revenue (TTM)
$5,371 Mln
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
5.1 %
Edit
| Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
10,434 | 1,155 | 878 | 923 | 7 |
Revenue ($ Mln) |
5,371 | 73 | 1,653 | 208 | -- |
Net Profit ($ Mln) |
-169.00 | 36.72 | 48.98 | 52.16 | -10.47 |
Net Margin (%) |
-3.15 | 50.13 | 2.96 | 25.13 | -- |
RoE (%) |
-1.85 | 11.69 | 3.61 | 30.61 | -130.80 |
Price to Earnings |
-- | 29.47 | 12.25 | 17.86 | -- |
Price-To-Book |
1.20 | 2.89 | 0.63 | 4.83 | 1.73 |
Income Statement ($ Mln)
| Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
5,355.00 | 34.76 | 1,676.50 | 148.47 | 0.00 |
|
Cost of Revenue
|
4,529.00 | 21.28 | 1,210.50 | 73.46 | -- |
|
Gross Profit
|
826.00 | 13.48 | 466.00 | 75.02 | -- |
|
Operating Expenses
|
574.00 | 7.64 | 250.60 | 20.76 | 4.24 |
|
Operating Profit (EBIT)
|
252.00 | 5.84 | 215.40 | 54.26 | -4.24 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-115.00 | 29.60 | 113.40 | 54.70 | -4.23 |
|
Provision for Tax
|
-2.00 | 9.27 | 37.20 | 20.96 | -- |
|
Profit after Tax (Net Income)
|
-98.00 | 20.33 | 76.20 | 33.74 | -4.23 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
8,246.00 | 233.96 | 1,328.50 | 150.73 | 11.22 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
8,394.00 | 151.17 | 1,373.80 | 28.86 | 0.22 |
|
Current Liabilities
|
1,548.00 | 32.88 | 574.30 | 28.85 | 0.14 |
|
Total Liabilities
|
19,185.00 | 418.01 | 3,276.60 | 208.45 | 11.58 |
Assets ($ Mln)
| Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
17,946.00 | 393.79 | 2,735.90 | 96.72 | 0.35 |
|
Current Assets
|
1,239.00 | 24.22 | 540.70 | 111.72 | 11.23 |
|
Total Assets
|
19,185.00 | 418.01 | 3,276.60 | 208.45 | 11.58 |
|
Total Debt*
|
8,657.00 | 141.00 | 1,225.30 | 0.07 | 0.35 |
|
Net Current Assets
|
-309.00 | -8.66 | -33.60 | 82.87 | 11.09 |
Cashflow ($ Mln)
| Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
943.00 | 16.95 | 322.00 | 52.98 | -10.48 |
|
Cash Flow from Investing Activities
|
-1,067.00 | -159.46 | -350.90 | -20.34 | -- |
|
Cash from Financing Activities
|
14.00 | 144.84 | 54.70 | 30.07 | 15.31 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-0.60 | 6.94 | 3.17 | 29.00 | -70.02 |
|
ROE (%)
|
-1.16 | 9.13 | 6.23 | 29.64 | -72.09 |
|
ROA (%)
|
-0.52 | 6.27 | 2.52 | 21.39 | -69.85 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-1.83 | 58.49 | 4.55 | 22.72 | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.00 | 1.89 | 0.14 | 0.61 | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
85.24 | 930.56 | 17.96 | 76.17 | -1,068.75 |
|
EPS Growth (%)
|
0.85 | 22.18 | -0.92 | 0.56 | -253.40 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-81.43 | -- | 10.27 | 15.37 | -0.10 |
|
Price / Book Value
|
0.97 | -- | 0.59 | 3.44 | 0.04 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
15.81 | -- | 5.70 | 6.90 | 1.00 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
1.05 | 0.60 | 0.92 | 0.00 | 0.03 |
|
Short term debt to equity ratio
|
0.02 | -- | 0.16 | 0.00 | 0.01 |
|
Current Ratio
|
0.80 | 0.74 | 0.94 | 3.87 | 81.93 |
|
Quick Ratio
|
0.71 | -- | 0.79 | 2.86 | -- |
|
Interest Coverage
|
0.57 | 3.43 | 2.87 | 55.05 | -493.92 |
Operating Efficiency Ratios
| Lineage, Inc. (LINE) | Viamet Pharmaceuticals Corp (VMET) | Republic Airways Holdings Inc (RJET) | MAKO Surgical Corp (MAKO) | Curanex Pharmaceuticals Inc (CURX) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
16.73 | 27.70 | 6.33 | 1.38 | -- |
|
Asset Turnover
|
0.28 | 0.11 | 0.55 | 0.94 | 0.00 |
|
Receivable days
|
58.73 | 52.53 | 17.21 | 2.99 | -- |
|
Inventory Days
|
13.39 | -- | 22.86 | 100.11 | -- |
|
Payable days
|
93.39 | 35.28 | 27.62 | 59.08 | -- |
|
Cash Conversion Cycle
|
-21.28 | -- | 12.44 | 44.01 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
